Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging

Q32 Bio Inc.

Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.
Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.
SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.
Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).
Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.